title: The efficacy of the combination of sertraline with buspirone for smoking cessation. A randomized clinical trial in nondepressed smokers.
abstract: In a double-blind placebo-controlled trial, we evaluated the efficacy of the combination of sertraline and buspirone plus cognitive-behavioral treatment to promote tobacco abstinence in individuals referred to a chemical dependency clinic. Ninety eight individuals 18-65 years of age were randomized to placebo or sertraline 25 mg/day for 2 days, followed by 50 mg from day 3 to 90, and buspirone 5 mg three times a day for 7 days, and 10 mg from day 8 to 90. The rate of continuous abstinence at the 26th week of follow-up, informed by the patient, was 43.5% in the active treatment group and 17.3% in the control group (p = 0.01). The odds ratio for continuous abstinence for the intervention group was 4.74 (95% CI 1.50-14.55) (adjusted for smoker households and number of cognitive sessions). Nicotine withdrawal symptoms were common in both groups (98.7% vs. 95.5% p = 0.37). The combination of sertraline and buspirone with cognitive-behavioral therapy was more effective than placebo and cognitive-behavioral therapy to promote smoking cessation.
authors: Department of Internal Medicine, Faculdade de Medicina, Universidade de Passo Fundo, Marcelino Ramos 111/401, Passo Fundo, RS 99010-160, Brazil.
authors: Jorge Luiz
authors: JL
authors: Carrão
authors: Leila Beltrami
authors: LB
authors: Moreira
authors: Flávio Danni
authors: FD
authors: Fuchs
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002065:Buspirone / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D015928:Cognitive Behavioral Therapy / Q000379:methods; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000523:psychology / Q000628:therapy*
chemical_list: D002065:Buspirone; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline